Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | CA4 | P22748 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | BBOX1 | O75936 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL1335834 | 1.00 | FFAR3 (0.56) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Succinic Acid SCHEMBL66882 | 1.00 | — | — | |
| Succinic Acid SCHEMBL7572857 | 0.96 | FFAR3 (0.53) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Succinic Acid SCHEMBL818672 | 0.96 | FFAR3 (0.53) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Succinic Acid SCHEMBL2349922 | 0.96 | FFAR3 (0.53) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Succinic Acid SCHEMBL503943 | 0.96 | FFAR3 (0.53) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Succinic Acid SCHEMBL19704478 | 0.96 | FFAR3 (0.53) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Succinic Acid SCHEMBL28100151 | 0.92 | FFAR3 (0.50) | FFAR3HDAC3HDAC1HDAC2HDAC8 | |
| Succinic Acid SCHEMBL1462992 | 0.91 | — | — | |
| Succinic Acid SCHEMBL21958272 | 0.91 | FFAR3 (0.56) | FFAR3HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220257689-A1 | CHEWING GUM COMPOSITIONS FOR THE TREATMENT OF MENSTRUAL PAIN | ADVANCED FEMALE TECH LLC (US) | 2022-08-18 | — | — | US | claimed |
| US-20220248707-A1 | CHEWING GUM COMPOSITIONS FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS | ADVANCED FEMALE TECH LLC (US) | 2022-08-11 | — | — | US | claimed |
| EP-3947536-A1 | METHOD FOR PRODUCING AN EXPANDED RIGID FOAM WITH SEALED PORES | Institut Mines Telecom (FR) | 2022-02-09 | — | — | EP | claimed |
| WO-2020193682-A1 | METHOD FOR PRODUCING AN EXPANDED RIGID FOAM WITH SEALED PORES | INSTITUT MINES TELECOM (FR) | 2020-10-01 | — | — | WO | claimed |
| US-20220257689-A1 | CHEWING GUM COMPOSITIONS FOR THE TREATMENT OF MENSTRUAL PAIN | ADVANCED FEMALE TECH LLC (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220248707-A1 | CHEWING GUM COMPOSITIONS FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS | ADVANCED FEMALE TECH LLC (US) | 2022-08-11 | — | — | US | disclosed |
| US-20220133741-A1 | AAntihistamines In Combination With A Range Of Substances For Improved Health | Requis Pharmaceuticals (US) | 2022-05-05 | — | — | US | disclosed |
| CN-108675695-B | Anti-seepage and anti-corrosion additive for harbor wharfs and preparation method thereof | 日照港集团有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-108675695-B | Anti-seepage and anti-corrosion additive for harbor wharfs and preparation method thereof | 日照港集团有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-109221109-A | A kind of Synergistic mite killing composition containing avermectin | 福建新农大正生物工程有限公司 | 2019-01-18 | — | — | CN | disclosed |
| CN-106538588-A | A kind of Synergistic insecticidal compositions containing double third ring worm esters | 深圳诺普信农化股份有限公司 | 2017-03-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220248707-A1 | CHEWING GUM COMPOSITIONS FOR THE TREATMENT OF MENOPAUSAL SYMPTOMS | PGR, SHBG, PGRMC1 | FFAR3 2838/4885HDAC3 1806/4885HDAC1 1295/4885 |
| US-20220257689-A1 | CHEWING GUM COMPOSITIONS FOR THE TREATMENT OF MENSTRUAL PAIN | PGR, MUC1, PGRMC1 | FFAR3 2957/4885HDAC3 878/4885HDAC1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.